493
Views
15
CrossRef citations to date
0
Altmetric
Clinical Focus: Cardiometabolic Conditions - Review

The effect of short message service intervention on glycemic control in diabetes: a systematic review and meta-analysis

, ORCID Icon & ORCID Icon
Pages 566-571 | Received 27 May 2019, Accepted 13 Sep 2019, Published online: 28 Sep 2019
 

ABSTRACT

Background: Compared with traditional outpatient follow up, short message service (SMS) provides more convenience for diabetes self-management. However, the feasibility, effectiveness, and satisfaction of SMS intervention remain unclear.

Methods: A systematic retrieval of databases, including PubMed, EMBASE, and Cochrane Library, was used to evaluate the effect of SMS on the diabetes glycemic control. Complete quantitative reports on the changes of glycosylated hemoglobin (HbA1c) before and after intervention were collected. The study type was limited to randomized controlled trials (RCTs).

Results: 13 RCTs were identified as eligible for this subject. Overall result revealed a statistical decline of HbA1c by -0.62% (95% CI -0.82 to -0.41). The longest intervention duration was 12 months with the noteworthy improvement of HbA1c by -1.63% (-2.27 to -0.99). Compared with control groups, five trials quantitatively demonstrated a significant decline in fasting plasma glucose (FPG) by -0.45 (95% CI -0.7 to -0.19) and -1.05 (95% CI -1.35 to -0.75) in 2-h postprandial blood glucose (2hPBG).

Conclusions: This meta-analysis demonstrated that text message intervention indeed leads to a decline in HbA1c and improvement of blood glucose control. No convincing evidence was found on quality of life improvement, satisfaction, body mass index (BMI), blood lipid levels, the frequency of hypoglycemia, self-monitoring of blood glucose or complications reduction.

Declaration of financial/other relationships

The authors have no financial or other relationships to disclose. A PGM peer reviewer on this manuscript discloses providing medical support for a company which produces and markets drugs to treat type 2 diabetes.

Declaration of interest

No potential conflict of interest was reported by the authors.

Additional information

Funding

This manuscript received no funding.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.